ATE337406T1 - Replikationsunfähige herpesviren zur verwendung in gentherapie - Google Patents

Replikationsunfähige herpesviren zur verwendung in gentherapie

Info

Publication number
ATE337406T1
ATE337406T1 AT00983421T AT00983421T ATE337406T1 AT E337406 T1 ATE337406 T1 AT E337406T1 AT 00983421 T AT00983421 T AT 00983421T AT 00983421 T AT00983421 T AT 00983421T AT E337406 T1 ATE337406 T1 AT E337406T1
Authority
AT
Austria
Prior art keywords
nervous system
central nervous
replicate
gene therapy
gene
Prior art date
Application number
AT00983421T
Other languages
English (en)
Inventor
Robert Stuart Coffin
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovex Ltd filed Critical Biovex Ltd
Application granted granted Critical
Publication of ATE337406T1 publication Critical patent/ATE337406T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00983421T 1999-12-22 2000-12-22 Replikationsunfähige herpesviren zur verwendung in gentherapie ATE337406T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930418.0A GB9930418D0 (en) 1999-12-22 1999-12-22 Replication incompetent herpes virus vectors

Publications (1)

Publication Number Publication Date
ATE337406T1 true ATE337406T1 (de) 2006-09-15

Family

ID=10866883

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983421T ATE337406T1 (de) 1999-12-22 2000-12-22 Replikationsunfähige herpesviren zur verwendung in gentherapie

Country Status (9)

Country Link
US (1) US6821753B2 (de)
EP (1) EP1240344B1 (de)
JP (1) JP2003518080A (de)
AT (1) ATE337406T1 (de)
AU (1) AU782932B2 (de)
CA (1) CA2395576A1 (de)
DE (1) DE60030324D1 (de)
GB (1) GB9930418D0 (de)
WO (1) WO2001046449A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930419D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
ATE312189T1 (de) 2000-01-21 2005-12-15 Biovex Ltd Virusstämme für die onkolytische behandlung von krebs
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
WO2005080581A2 (en) * 2004-02-17 2005-09-01 University Of Florida Research Foundation, Inc. Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
JP4903689B2 (ja) * 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
AU2005302408B2 (en) * 2004-10-28 2012-08-09 The Government of the United States of America as represented by the Department of Veterans Affairs Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US20100192236A1 (en) * 2009-01-28 2010-07-29 University Of South Carolina Modulation of Delta Opioid Receptor Expression
US20100284977A1 (en) * 2009-04-28 2010-11-11 University Of South Carolina Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
RU2020105656A (ru) * 2013-07-17 2021-01-27 Юниверсити Оф Питтсбург- Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Нетоксичные векторы на основе впг для применений в эффективной доставке генов и комплементирующие клетки для их продуцирования
KR102490462B1 (ko) 2013-10-28 2023-01-19 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양분해성 hsv 벡터
US10011199B2 (en) 2014-10-30 2018-07-03 Diono, Llc Rear facing ride down safety seat
ES2919953T3 (es) 2016-01-27 2022-07-29 Oncorus Inc Vectores víricos oncolíticos y usos de los mismos
SI3377637T1 (sl) 2016-04-08 2020-08-31 Krystal Biotech, Inc. Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
RU2771110C2 (ru) 2017-07-26 2022-04-26 Онкорус, Инк. Онколитические вирусные векторы и их применение
WO2019200163A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
CN112041434A (zh) 2018-04-27 2020-12-04 克里斯托生物技术股份有限公司 用于美容性应用的编码一种或多种美容蛋白的重组核酸
CA3112627A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
MX2021008832A (es) 2019-02-08 2021-09-08 Krystal Biotech Inc Composiciones y metodos para la administracion de polipeptidos cftr.
US12209250B2 (en) 2019-03-14 2025-01-28 Massachusetts Institute Of Technology Engineered Herpes Simplex Virus-1 (HSV-1) vectors and uses thereof
EP4288140A1 (de) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvante therapie für krebs
AU2022246917A1 (en) 2021-04-02 2023-10-12 Krystal Biotech, Inc. Viral vectors for cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
GB9810904D0 (en) * 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof

Also Published As

Publication number Publication date
WO2001046449A1 (en) 2001-06-28
EP1240344A1 (de) 2002-09-18
AU2017501A (en) 2001-07-03
AU782932B2 (en) 2005-09-08
CA2395576A1 (en) 2001-06-28
EP1240344B1 (de) 2006-08-23
GB9930418D0 (en) 2000-02-16
DE60030324D1 (de) 2006-10-05
US6821753B2 (en) 2004-11-23
US20030082142A1 (en) 2003-05-01
JP2003518080A (ja) 2003-06-03

Similar Documents

Publication Publication Date Title
DE60030324D1 (de) Replikationsunfähige herpesviren zur verwendung in gentherapie
Palmer et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system
Contreras et al. PDGF-PDGFR network differentially regulates the fate, migration, proliferation, and cell cycle progression of myogenic cells
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
Thomas et al. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases
Folini et al. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells
Moriuchi et al. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model
Perng et al. A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation
Smith Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy
DE69835085D1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
JP7184337B2 (ja) 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現
DE69024809D1 (de) Herpes simplex virus typ 1 mutante
Isacson et al. Future of cell and gene therapies for Parkinson's disease
DK0998568T3 (da) Mutant med uracil phosphoribosyltransferaseaktivitet
WO2003016499A3 (en) Combinatorial methods for inducing cancer cell death
ATE282708T1 (de) Herpes-virusstämme für die gentherapie
CA2361892A1 (en) Treatment of tumors with genetically engineered herpes virus
IL181695A0 (en) Methods for cultivating cells and propagating viruses
Chancellor et al. Nitric oxide synthase gene transfer for erectile dysfunction in a rat model
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
Fukuhara et al. Triple‐mutated oncolytic herpes virus for treating both fast‐and slow‐growing tumors
ZA952433B (en) Recombinant viruses their preparation and their use in gene therapy
Cai et al. Recent advances and current status of gene therapy for epilepsy
MX2022001080A (es) Metodos y composiciones para reducir la inmunogenicidad mediante inhibidores de celulas b no agotadores.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties